Miltenyi Biotec, a global biomedical discovery and cellular therapy solutions provider based in Bergisch Gladbach, Germany, is expanding its presence in India with the establishment of its first office and the creation of an innovation and technology center in Hyderabad. This center is designated as a Cell and Gene Therapy Centre of Excellence (COE) and will serve as one of the company’s initial facilities in India.
The COE aims to provide a comprehensive learning environment for scientists, researchers, industry experts, and clinicians. It will offer classroom and hands-on training on cell and gene therapy approaches, covering the entire spectrum from proof of concept to pre-clinical and clinical development, and eventual commercialization. This facility is expected to facilitate easier access to expertise, research, and manufacturing solutions for Indian researchers, scientists, and clinicians.
Miltenyi Biotec is globally recognized for its contributions to cell and gene therapy, offering devices, technology solutions, automated workflows, and services for research and development through commercialization. The company’s CliniMACS Prodigy platform is a key component, designed for end-to-end clinical development and manufacturing of cell and gene therapy in an automated and functionally closed system suitable for both small and large-scale production.
The company’s technologies have played a significant role in treating over 10,000 patients annually with cell products, with more than 950 investigational new drug (IND) applications and investigational device exemptions (IDE) submitted to the US FDA utilizing Miltenyi Biotec’s technologies and platforms.
The announcement of the Hyderabad center follows a meeting with Telangana Chief Minister Revanth Reddy, who emphasized its importance in advancing novel therapies within the scientific community and extending healthcare options for patients not only in India but globally.
Dr. Boris Stoffel, Managing Director of Miltenyi Biotec, highlighted the company’s commitment to fostering knowledge exchange and forming public-private partnerships like recent MOU with BIRAC, DBT as CGT partner. He emphasized the single-minded focus on driving accessibility, affordability, and availability of cell and gene therapies through local development and manufacturing in India. Additionally, the company expressed its intent to catalyze the development of Chimeric Antigen Receptor (CAR) T cell clinical development and manufacturing, potentially bringing CAR T cell therapy to hospitals across India.